Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients

Carlos Besses, Alberto Álvarez-Larrán, Luz Martínez-Avilés, Sergi Mojal, Raquel Longarón, Antonio Salar, Lourdes Florensa, Sergi Serrano, Beatriz Bellosillo

Research output: Contribution to journalArticleResearchpeer-review

24 Citations (Scopus)

Abstract

The modulation of JAK2 V617F allele burden dynamics was prospectively analysed in 47 patients (26 polycythaemia vera [PV] and 21 essential thrombocythaemia [ET]) treated with first-line hydroxyurea (HU) and compared with the JAK2 V617F dynamics of a control group of 45 PV and ET patients. A partial molecular response (PMR), according to European Leukaemia Net criteria, was observed in 27/47 (57%) patients. Median time to PMR was 14months (3-66) with a probability of PMR at 3years of 57%. A significant decrease in JAK2 V617F allele load was observed at 36months both in PV and ET patients, being the reduction in PV higher than in ET patients (P=0·01). A haematocrit ≥0·45L/L was associated with a higher probability of attaining a PMR (HR:3·4; 95%CI:1·02-11·6, P=0·04). Control group showed a slight increase of JAK2 V617F allele burden over time. The reduction in the mutated allele load comparing treated patients versus controls was highly significant both in PV and ET, demonstrating a clear effect of HU on the JAK2 V617F allele burden. In conclusion, first-line HU can attain PMR in more than 50% of newly diagnosed PV and ET patients, with a continuous decrease of the JAK2 V617F allele burden in PV patients during treatment. © 2011 Blackwell Publishing Ltd.
Original languageEnglish
Pages (from-to)413-419
JournalBritish Journal of Haematology
Volume152
Issue number4
DOIs
Publication statusPublished - 1 Feb 2011

Keywords

  • Allele burden
  • Essential thrombocythaemia
  • Hydroxyurea
  • JAK2 V617F
  • Polycythaemia vera

Fingerprint Dive into the research topics of 'Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients'. Together they form a unique fingerprint.

Cite this